BCM Industries Inc
Human Kidneys Expected to Regenerate Tissue and Reverse Chronic Kidney Disease
Updated: Feb 3, 2021
Clinical Trial Results Imminent
For Immediate Release: February 2, 2021
Repairing a diseased or injured kidney by regenerating new tissue has always been impossible. Human kidneys are not able to regenerate tissue; or are they?
BCM Industries, a global leader in regenerative tissue organ repair, is on the verge of establishing that human kidneys can in fact regenerate tissue, thereby self-repairing, addressing many forms of Chronic Kidney Disease (CKD), and avoiding renal failure. This is an astounding advancement in Medical Science and Healthcare.
Autologous Regenerative Tissue Replacement (ARTR™) is a technology and process invented and delivered by BCM, enabling customized treatments and procedures to stimulate and support a human kidney to regenerate and repair. An ARTR™ procedure involves using live tissue samples from the patient’s diseased organs to grow healthy organ tissue that is then surgically implanted into the failing organ. The ARTR™ implant immediately starts to regenerate new tissue, thereby improving organ health. ARTR™ is an alternative to organ transplants, which are a more complex surgery and often not available due to limited organ donors. Transplants also require expensive and risky drug suppression of the patient’s immune system. By using the patient’s own tissues, the result is a DNA-matched miracle of nature – stimulating the body’s natural cellular ability to repair itself.
A formal medical announcement of the success of BCM created ARTR™ organ repair treatments will soon be released by Dr. Liaqat Ali, MD. MBBS, CHPE, FCPS (Urology) Chairman Urology & Transplant Institute of Kidney Diseases, Hayatabad Medical Complex, Peshawar, Pakistan, and Chief Surgeon of ARTR™ Kidney Repair Surgeries.
The imminent clinical trial results will necessitate the re-writing of medical textbooks based on a newly discovered fact – that human organs can regenerate tissue. This innovation will also trigger radical changes to organ treatments, medical procedures, and healthcare – and deliver significantly improved outcomes and treatment success rates.
During 2021, new ARTR™ organ treatments will become available to regenerate and repair livers, lungs, and pancreases – in addition to kidneys. These new procedures can treat various organ diseases and injuries, return organs to healthy functionality, and offer an alternative to organ transplants.
BCM’s continuing expansion of ARTR™ treatment applications will focus on addressing CKD, CLD, COPD, Type 1 and 2 Diabetes, post COVID-19 damage, and other organ health issues. BCM is also working to address heart muscle regeneration and repair, cartilage and bone regeneration, and cancer treatment enhancements.
BCM Industries is a U.S. pharmaceutical company, and a global leader in regenerative tissue organ repair through the creation and delivery of ARTR™ treatments and procedures customized to each patient, their organ, and the disease or issue. To learn more visit: https://www.bcmindustries.com